- Subject
- Mental Health
- Filed
- Source
- Thomas Miller
- Loans
- 662
Psilocybin and the Return of Pleasure: What a Small Early Trial Shows
A small pilot trial links psilocybin to lasting relief from depression and early, mixed gains in pleasure. Promising, but far from settled.

Maybe the coffee tastes flat, or the group chat goes unanswered, or the record you used to play on repeat barely registers. Many people with depression describe this kind of quiet flattening, and it can persist even after other symptoms ease. Clinicians call it anhedonia, and it's the focus of a new early study exploring whether psilocybin, the compound found in certain mushrooms, could help restore that lost sense of enjoyment.

What anhedonia is, and why it's hard to treat
Anhedonia is the reduced ability to feel interest or pleasure in things that once felt rewarding. It can show up around food, relationships, hobbies, and sensory experiences. The researchers behind this work cite estimates that it affects 82% to 92% of people with major depression, which makes it far from a niche symptom.
What makes it especially stubborn is that it doesn't always lift when mood improves. Someone might sleep better, feel less hopeless, and function more normally, yet still find that a favorite meal or a weekend outing doesn't land the way it used to. Anhedonia has also been linked to greater treatment resistance, lower quality of life, and suicidal thoughts and behaviors, which is why researchers pay close attention to it as a separate target rather than assuming it will resolve on its own.
Inside the pilot study
Researchers at the University of Colorado Anschutz Medical Campus set out to answer a narrower question than most psilocybin research asks. Earlier trials have largely tracked depression as a whole. This team wanted to know whether psilocybin could specifically improve the capacity for pleasure.
They enrolled 20 adults with treatment-resistant depression, meaning their symptoms hadn't improved enough with standard treatments. Participants received either 25 milligrams of psilocybin or a 1-milligram comparison dose, and both groups received psychological support alongside the dose. The small comparison dose serves as a control, giving researchers a baseline to measure the larger dose against.

Pleasure was measured with two different questionnaires. The first looked at interest, motivation, and enjoyment across everyday life, including eating, socializing, hobbies, and sensory experiences. The second was an established pleasure scale that has appeared in earlier psilocybin research. Depression symptoms were tracked as well, with follow-up assessments at one week and eight weeks after treatment.
One design detail stands out. Unlike many earlier psilocybin trials, participants didn't have to stop their usual antidepressants before treatment. For people who rely on those medications to stay stable, stopping can be difficult and carries its own risks, so a study that allows them to continue reflects a more realistic picture of care.
Mood improved, and pleasure moved more slowly
The clearest result concerned depression. One week after treatment, participants who received 25 milligrams showed a greater reduction in overall depression symptoms than those who received the 1-milligram dose. That improvement was still evident at eight weeks, which matters because short-lived mood shifts are a common concern with fast-acting interventions.
The results for pleasure were more uneven. On the first questionnaire, the gap between the two groups at the one-week check was too small to rule out chance. In plain terms, the trial didn't meet its main goal on that measure at that point. By week eight, though, participants in the 25-milligram group showed greater improvements in interest, motivation, and enjoyment on that same scale.

The second questionnaire told a slightly different story. It favored the 25-milligram group at one week, but that difference was less pronounced by eight weeks. So one measure showed a late gain, while the other showed an early advantage that faded. Both are informative, but neither is a clean, consistent win.
How much weight the findings can bear
With 20 participants, this is a pilot study. It was designed to test feasibility and generate direction for larger work, not to establish whether psilocybin reliably restores pleasure for most people. The researchers themselves framed the findings as suggestive: psilocybin may help with both depression and the ability to experience pleasure, but the strength and timing of the effects depended on how they were measured.
That's a sensible read. A small sample can produce results that look stronger or weaker than they would across a broader population. The gap between the groups on the first pleasure measure didn't reach the threshold that would rule out chance, and the second measure's early benefit didn't hold. Those details shouldn't get lost in a headline about mushrooms and joy.
Still, the study does something useful. It separates anhedonia from depression in its design, asks whether the two respond to treatment in the same way, and does so in people whose depression hasn't responded well to standard care. Those are the questions a larger trial would need to answer, and this one points to where the measurement effort should go.
What this means if you're living with flat pleasure
If the things you love have started to feel distant, a few practical steps are worth considering. Start by noticing what has changed. Is it socializing, food, exercise, hobbies, or several things at once? Writing down when the shift seems worse can reveal patterns that are useful to bring to a clinician.
Keeping some enjoyable activities in your routine can also help, even when motivation is low. A short walk, a familiar hobby, or a conversation with someone you trust doesn't need to produce a burst of happiness to be worthwhile. The aim is to stay connected to things that matter to you while you figure out what's going on.
Persistent loss of pleasure deserves a conversation with a mental health professional, particularly if it's affecting work, relationships, or daily routines. A clinician can help determine whether anhedonia or another concern is contributing and discuss options that fit your situation.
What about psilocybin specifically? Please don't experiment with it on your own. It remains under study as a depression treatment and should only be considered within a supervised research setting. If you take antidepressants, don't stop or change them without speaking to your prescriber first. Stopping suddenly can cause problems of its own.
The takeaway
Feeling less depressed and enjoying life again aren't always the same thing, and this early work takes that distinction seriously. Psilocybin showed a meaningful edge on depression symptoms that held for eight weeks, and its effects on pleasure look promising but inconsistent so far. My read is that the next step is a larger trial that measures pleasure in a way that can clearly separate it from mood. Until that exists, the most useful move is a candid conversation with your care team about what you're noticing.
Source: pilot clinical trial, University of Colorado Anschutz Medical Campus